^
    No biomarker
    Penile Cancer
    paclitaxel
    Sensitive: A2 - Guideline
    No biomarker
    Penile Cancer
    capecitabine
    Sensitive: A2 - Guideline
    No biomarker
    Penile Cancer
    cetuximab
    Sensitive: A2 - Guideline
    No biomarker
    Penile Cancer
    cisplatin
    Sensitive: A2 - Guideline
    No biomarker
    Penile Cancer
    5-fluorouracil + mitomycin
    Sensitive: A2 - Guideline
    No biomarker
    Penile Cancer
    carboplatin + paclitaxel
    Sensitive: A2 - Guideline
    No biomarker
    Penile Cancer
    cisplatin + irinotecan
    Sensitive: A2 - Guideline
    No biomarker
    Penile Cancer
    cisplatin + 5-fluorouracil
    Sensitive: A2 - Guideline
    No biomarker
    Penile Cancer
    imiquimod
    Sensitive: A2 - Guideline
    No biomarker
    Penile Cancer
    5-fluorouracil
    Sensitive: A2 - Guideline
    No biomarker
    Penile Cancer
    TIP
    Sensitive: A2 - Guideline
    MSI-H/dMMR
    Penile Cancer
    pembrolizumab
    Sensitive: A2 - Guideline
    TMB-H
    Penile Cancer
    pembrolizumab
    Sensitive: C1 - Off-label
    PD-L1 expression
    Penile Cancer
    pembrolizumab
    Sensitive: C1 - Off-label
    TMB-H + PD-L1 expression + MSI-L/dMMR
    Penile Cancer
    nivolumab + ipilimumab
    Sensitive: C4 – Case Studies
    TMB-H + PD-L1 expression
    Penile Cancer
    toripalimab
    Sensitive: C4 – Case Studies
    CDKN2A mutation
    Penile Cancer
    nivolumab
    Sensitive: C4 – Case Studies